Stifel Reiterates Buy Rating on Horizon Therapeutics (HZNP) on Bullish Tepezza Survey
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $138.00 price target on Horizon Therapeutics (NASDAQ: HZNP) after a Tepezza ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
